4//SEC Filing
Sun BioPharma, Inc. 4
Accession 0001437749-17-005015
CIK 0001029125operating
Filed
Mar 20, 8:00 PM ET
Accepted
Mar 21, 5:07 PM ET
Size
6.5 KB
Accession
0001437749-17-005015
Insider Transaction Report
Form 4
GILBERTSON RYAN RANDALL
10% Owner
Transactions
- Award
Convertible Promissory Note
2017-03-17$200000.00/sh+200,000$40,000,000,000→ 200,000 total(indirect: Northern Capital Partners I, LP)Exercise: $1.01From: 2017-03-17Exp: 2018-12-01→ Common Stock (198,020 underlying)
Footnotes (3)
- [F1]Convertible into issuer common stock a price of $1.01 per share upon reporting person's election. Upon a "qualified financing", automatically converts into common stock at the foregoing price per share or (if less) a price representing a 33% discount from either (a) the price per share of common stock (if any) offered in such financing or (b) the closing price of issuer common stock on the date the material terms of such financing are first publicly announced, subject to reporting person's right to elect an alternate conversion into the securities then offered at a 10% discount to the price paid in the financing. Upon a corporate transaction, automatically converts into common stock at a price equal to $30 million divided the number of issuer common stock outstanding (calculated on a fully-diluted basis).
- [F2]Represents original principal amount.
- [F3]Represents shares of issuer common stock into which the outstanding principal amount was convertible upon the date of the transaction. Does not include shares issuable upon conversion of unpaid interest, which accrues at a rate of 5.0% per annum.
Documents
Issuer
Sun BioPharma, Inc.
CIK 0001029125
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001029125
Filing Metadata
- Form type
- 4
- Filed
- Mar 20, 8:00 PM ET
- Accepted
- Mar 21, 5:07 PM ET
- Size
- 6.5 KB